Clinical Trials Directory
We are doing this study to find out if the use of continuous glucose monitors (CGMs) is worthwhile to help breast cancer patients and their providers monitor for hyperglycemia, or high blood sugar, during chemotherapy. A CGM is a small, wearable sensor that is attached to the skin to frequently measure your blood sugar level, and can share the measurements to your smartphone and to your medical team.
We are doing this study to see whether programs are helpful for couples where one partner has cancer.
We are doing this study to better understand how breast cancer treatment can affect the heart. In particular, we want to know if treatment with near complete estrogen deprivation (NCED) therapy has an impact on heart function.
We are doing this study to find out if an experimental drug called CTX131 (the study drug) is a safe and effective treatment for different forms of cancer with solid tumors. The study drug is made from white blood cells or T cells from healthy donors.
We are doing this study to find out if using ice with or without compression during chemotherapy can prevent neuropathy for patients being treated for gynecologic cancer.
We are doing this study learn more about circulating immune cells and circulating tumor cells (CTCs) in patients with metastatic renal cell carcinoma or metastatic urothelial carcinoma. We are also looking at the bacteria in your gut and urinary tract to learn about how these bacteria affect how your cancer responds to immunotherapy.
We are doing this study to find out if an experimental drug called CT01681 (the study drug) is a safe and effective option for people who get CAR T-cell therapy as a treatment for diffuse large B cell lymphoma (DLBCL). We want to know if the study drug has the potential to lower or prevent certain side effects of CAR T-cell therapy. The possible side effects of CAR T-cell therapy that the study drug is being developed to protect against are called cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. This study is enrolling people who will receive an available form of CAR T-cell therapy called YESCARTA.
We are doing this study to see if an experimental combination of drugs (D2C7-IT and 2141-V11) is a safe treatment for brain tumors.